Healthcare utilization and costs associated with acute lymphoblastic leukemia in children with and without Down syndrome
Journal Articles
Overview
Research
Identity
Additional Document Info
View All
Overview
abstract
AbstractBackgroundChildren with Down syndrome (DS) and acute lymphoblastic leukemia (ALL) are at increased risk of treatment‐related morbidity and mortality compared to non‐DS‐ALL, requiring increased supportive care. We examined the healthcare utilization and costs in DS‐ALL patients to inform future evaluations of novel therapies.MethodsA provincial registry identified all children (1–17 years) diagnosed with B‐lineage ALL in Ontario, Canada between 2002 and 2012. Detailed demographic, disease, treatment, and outcome data were abstracted. Linkage to population‐based health services databases identified all outpatient and emergency department (ED) visits, hospitalizations, and physician billings. Healthcare utilization costs were available for patients diagnosed during 2006–2012 using validated algorithms (2018 Canadian dollars). Healthcare utilization rates and costs were compared between DS and non‐DS patients using regression models, adjusting for all covariates.ResultsOf 711 patients, 28 (3.9%) had DS. Adjusting for all covariates, children with DS‐ALL experienced substantially higher rates of ED visits (rate ratio [RR] 1.5, 95% confidence interval [95% CI]: 1.2–2.0; p = .001) and inpatient days (RR 2.5, 95% CI: 1.4–4.5; p = .002) compared to non‐DS children. Outpatient visit rates were similar (RR 1.1, 95% CI: 0.9–1.3; p = .41). Among patients with available cost data (N = 533, DS = 19), median 5‐year healthcare utilization cost was $247,700 among DS patients (interquartile range [IQR]: 200,900–354,500) and $196,200 among non‐DS patients (IQR: 148,900–280,300; p = .02). In adjusted analyses, DS‐associated costs were 50% higher (RR 1.5, 95% CI: 1.2–1.9; p < .002).ConclusionsHealthcare utilization and treatment costs of DS‐ALL patients are substantially higher than those of non‐DS‐ALL. Our data provide a baseline for future DS‐specific cost‐effectiveness studies.
